Diantha Duvall - 02 Jun 2022 Form 4 Insider Report for GENOCEA BIOSCIENCES, INC.

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: N/A
Reported as of: 02 Jun 2022
Net transaction value: -$81.3
SEC form: 4
Accepted by SEC: 03 Jun 2022, 16:13:21 UTC
Prior SEC filing: 26 May 2022
Next SEC filing: 10 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Diantha Duvall

Filing notes and source

Key filing fact

Diantha Duvall filed Form 4 for GENOCEA BIOSCIENCES, INC. on 03 Jun 2022.

Key facts

This page summarizes Diantha Duvall's Form 4 filing for GENOCEA BIOSCIENCES, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jun 2022, 16:13.

Change

Previous filing in this sequence was filed on 26 May 2022.
Current net transaction value: -$81.3.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GNCA transaction

Common Stock

Sale

Transaction value: -$81.3
Shares: -1,355
Change %: -1.8%
Price: $0.0600^*
Shares after: 75,388
Date: 02 Jun 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.